Objective: The aim of this study was to examine immediate-release methylphenidate
effectiveness during the 10-month open-label continuation phase of the Preschoolers with …

Attention deficit/hyperactivity disorder (ADHD) symptoms are common in youth with autism
spectrum disorders (ASD) and are frequently treated with stimulant medications. Twenty …

Objective. The objective of this study was to evaluate differences in the pharmacodynamic
(PD) profile of 2 second-generation extended-release (ER) formulations of methylphenidate …

Objective: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the
treatment of patients aged≥ 6 years with attention-deficit/hyperactivity disorder (ADHD). A …

Background The stimulant methylphenidate (MPH) has been a mainstay of treatment for
attention-deficit/hyperactivity disorder (ADHD) for many years. Owing to the short half-life …

Objective To compare the efficacy and safety of two methylphenidate (MPH) formulations—
once-daily modified-release MPH (EqXL, Equasym™ XL) and twice-daily immediate-release …

Aim This study investigated whether components of attention and executive functioning
improve when children with attention‐deficit–hyperactivity disorder (ADHD) are treated with …

Background The main aim of this study was to compare the safety and efficacy of IR MPH
administered three times daily to those of once daily OROS-MPH. Methods Subjects were …

OBJECTIVE:: This study compared once-daily dexmethylphenidate extended release (D-
MPH-ER) 20 mg/day and placebo over 12 hours in children ages 6 to 12 with attention …

Objectives. Methylphenidate (MPH) is effective for adults with attention-deficit/hyperactivity
disorder (ADHD). This study aimed to evaluate the efficacy and safety of OROS MPH in …